However, a study by Vanella et al. demonstrated that ellagic acid, an antioxidant with potential chemotherapeutic properties, may act to inhibit tumor growth by decreasing EET formation, specifically by downregulating CYP2J2 and upregulating soluble epoxide (sEH) expression in a prostate cancer cell line (Vanella et al., 2013). This evidence concerns the gene CYP2J2 and prostate carcinoma.